Avalanche Biotechnologies, Inc. (AAVL) is a publicly traded company in the Unknown sector. Across all available filings, 17 corporate insiders have executed 140 transactions totaling $86.3M, demonstrating a bullish sentiment with $24.7M in net insider flow. The most recent transaction on Feb 29, 2016 involved a transaction of 3,907 shares valued at $0.
No significant insider buying has been recorded for AAVL in the recent period.
No significant insider selling has been recorded for AAVL in the recent period.
Based on recent SEC filings, insider sentiment for AAVL is bullish with an Insider Alignment Score of 64/100 and a net flow of $24.7M. Insiders are accumulating shares, which historically signals confidence in the company's future performance.
Insider trading at Avalanche Biotechnologies, Inc. (AAVL) refers to stock transactions made by corporate insiders—executives, directors, and beneficial owners holding more than 10% of the company's shares. These individuals have access to material non-public information and are required by law to report their trades to the SEC within two business days. Currently, 17 insiders are actively trading AAVL stock, having executed 140 transactions in the past 90 days. The most active insider is Special Situations Fund, L.p. Deerfield (Executive), who has made 24 transactions totaling $31.9M.
Get notified when executives and directors at AAVL file new Form 4 transactions
Date | Insider | Title | Type | Shares | Price | Value | Flags |
|---|---|---|---|---|---|---|---|
| Feb 29, 2016 | Wachter Paul | Executive | Award | 3,907 | $N/A | $0 | |
| Feb 12, 2016 | Braun Shirley | Executive | Award | 116,900 | $N/A | $0 | |
| Feb 12, 2016 | Swartzburg Michael | Executive | Award | 36,900 | $N/A | $0 | |
| Feb 12, 2016 | B. Barone Samuel | Executive | Award | 50,000 | $N/A | $0 | |
| Feb 12, 2016 | G. Rubio Roman | Executive | Award | 50,000 | $N/A | $0 | |
| Feb 12, 2016 | Gasmi Mehdi | Executive | Award | 125,000 | $N/A | $0 | |
| Feb 12, 2016 | Wachter Paul | Executive | Award | 8,333 | $N/A | $0 | |
| Feb 12, 2016 | S. Blumenkranz Mark | Executive | Award | 8,333 | $N/A | $0 | |
| Feb 12, 2016 | Daniel Schwartz Steven | Executive | Award | 8,333 | $N/A | $0 | |
| Feb 12, 2016 | Peter Mclaughlin John | Executive | Award | 8,333 | $N/A | $0 | |
| Jan 29, 2016 | Wachter Paul | Executive | Award | 3,334 | $N/A | $0 | |
| Dec 31, 2015 | Wachter Paul | Executive | Award | 2,101 | $N/A | $0 | |
| Nov 30, 2015 | Wachter Paul | Executive | Award | 1,909 | $N/A | $0 | |
| Oct 30, 2015 | Wachter Paul | Executive | Award | 2,373 | $N/A | $0 | |
| Sep 30, 2015 | Wachter Paul | Executive | Award | 2,428 | $N/A | $0 |
| TYPE | COUNT | VALUE | % |
|---|---|---|---|
Purchase(P) | 24 | $55.5M | 64.3% |
Sale(S) | 49 | $30.8M | 35.6% |
Exercise(M) | 12 | $52.8K | 0.1% |
Exercise (Options)(X) | 2 | $8.8K | 0.0% |
Award(A) | 32 | $0 | 0.0% |
Gift(G) | 2 | $0 | 0.0% |
Conversion(C) | 19 | $0 | 0.0% |
Insiders at Avalanche Biotechnologies, Inc. are accumulating shares at an accelerated pace. With 17 insiders making 140 transactions totaling $55.5M in purchases versus $30.8M in sales, the net buying activity of $24.7M signals strong executive confidence. Special Situations Fund, L.p. Deerfield (Executive) leads the buying activity with $31.9M in transactions across all time.